Salivary Melatonin Profile: What This Test Actually Measures

What a Salivary Melatonin Profile Actually Tests

A salivary melatonin profile does not produce a single number the way a fasting glucose test does. It produces a time-series curve. Saliva samples are collected every 30 to 60 minutes across the evening, typically starting 5 to 6 hours before your habitual bedtime and continuing until roughly 30 minutes after you normally fall asleep. Each sample is analyzed by enzyme-linked immunosorbent assay (ELISA) or mass spectrometry for melatonin concentration in pg/mL. The curve those values trace tells a clinician not just how much melatonin your pineal gland secretes, but when secretion starts, how steep the rise is, and whether the profile matches your reported sleep timing.

Why Saliva Rather Than Blood or Urine

Salivary melatonin closely tracks free (unbound) plasma melatonin, with a salivary-to-plasma ratio of approximately 0.24 to 0.33 at physiological concentrations. A 2008 analysis by Benloucif et al. Published in the Journal of Pineal Research confirmed that salivary DLMO and plasma DLMO agree within about 8 minutes on average. Saliva collection is non-invasive, does not require venipuncture in dim light (which would disturb the measurement), and can be completed entirely at home with a temperature-controlled mailing kit.

Urinary 6-sulfatoxymelatonin (aMT6s) is an alternative that reflects the prior night's total melatonin output, but it cannot pinpoint DLMO timing. Serum sampling requires a clinic stay in controlled low-light conditions, adding cost and logistical barriers. Saliva is therefore the preferred biofluid for outpatient circadian phase assessment.

The DLMO Calculation

Labs compute DLMO using one of two methods. The fixed-threshold method sets DLMO at the first of at least two consecutive samples exceeding 3 pg/mL (or 4 pg/mL in some commercial protocols). The mean-based threshold method sets DLMO at the first sample exceeding the mean of the three lowest daytime samples plus two standard deviations. The Endocrine Society's 2015 Clinical Practice Guideline on melatonin treatment of circadian rhythm sleep-wake disorders endorses DLMO as the gold-standard circadian phase marker and recommends the fixed 3 pg/mL threshold for clinical practice.

Both methods are valid. Knowing which threshold your lab uses matters when comparing results across time.

Normal Ranges: What the Numbers Mean

A "normal" salivary melatonin result covers three separate questions: is the DLMO time appropriate for the reported sleep schedule, is the peak concentration sufficient, and is the rate of rise biologically normal?

DLMO Timing

In adults with a conventional sleep schedule (bedtime near 23:00), DLMO occurs between approximately 21:00 and 22:30. A 2005 study by Burgess and Eastman (N=63 healthy adults) found mean DLMO at 21:44 ± 1.1 hours under standardized dim-light conditions. That study is indexed at PubMed here. DLMO typically precedes habitual sleep onset by 1.5 to 2.5 hours in phase-normal individuals.

DLMO before 19:30 indicates an advanced circadian phase. DLMO after 23:30 indicates a delayed circadian phase. Both are clinically significant even when a person reports "normal" sleep duration, because misalignment between internal phase and social clock time drives sleep fragmentation, mood disruption, and metabolic dysregulation.

Peak Melatonin Concentration

Peak salivary melatonin in healthy adults aged 20 to 40 typically falls between 80 and 120 pg/mL, measured at approximately 02:00 to 04:00 in a dark environment. Values decline with age: adults over 65 may have peaks of 40 to 60 pg/mL, a drop thought to reflect reduced pineal calcification and sympathetic input rather than disease. A 1999 study by Zeitzer et al. In the Journal of Clinical Endocrinology and Metabolism (N=34) documented this age-related decline in nocturnal melatonin amplitude.

Peak values below 20 pg/mL are considered low-amplitude and may reflect light pollution during sleep, beta-blocker use, excessive nonsteroidal anti-inflammatory drug (NSAID) exposure, or pineal gland dysfunction.

Rate of Rise

A physiologically normal melatonin curve rises from baseline (<2 pg/mL) to peak concentrations within 3 to 4 hours. A blunted slope (exceeding 5 to 6 hours to reach half-peak) suggests either suppressed secretion or marked circadian disruption. Labs rarely report slope as a standalone metric, but the raw time-series data allows a clinician to calculate it.

What a High Salivary Melatonin Result Means

"High" melatonin on this test can mean two different things: an earlier-than-expected DLMO (advanced phase) or a higher-than-expected peak concentration. They carry distinct clinical implications.

Advanced DLMO (Phase Advance)

DLMO before 19:30 characterizes Advanced Sleep-Wake Phase Disorder (ASWPD). Affected individuals feel sleepy in the early evening (18:00 to 20:00), fall asleep very early, and wake spontaneously in the early morning hours (03:00 to 05:00). The American Academy of Sleep Medicine (AASM) International Classification of Sleep Disorders, Third Edition (ICSD-3) lists ASWPD as a circadian rhythm sleep-wake disorder with a known circadian basis.

Familial cases carry mutations in PER2, CRY1, and CK1-delta. Evening bright-light therapy (2,500 lux for 2 hours starting around 20:00) is the first-line treatment for most non-familial ASWPD.

Elevated Peak Concentration

Salivary peaks above 200 pg/mL are uncommon in adults and may reflect recent exogenous melatonin use, which can persist in saliva longer than in serum. Patients must disclose and stop all melatonin supplements at least 7 to 10 days before testing. Isolated high peak without phase shift is rarely pathological in adults, but very high concentrations (>400 pg/mL) in children warrant pediatric endocrinology referral to rule out pinealoma or other structural pathology.

What a Low Salivary Melatonin Result Means

Low melatonin on the profile means either a delayed DLMO, a blunted peak, or both.

Delayed DLMO (Phase Delay)

DLMO after 23:30 is the hallmark of Delayed Sleep-Wake Phase Disorder (DSWPD). Prevalence reaches approximately 7% to 16% in adolescents and 0.17% in general adult populations based on large sleep-center registry data. A 2017 meta-analysis by Micic et al. Published in Sleep Medicine Reviews estimated the adult DSWPD prevalence at 0.17% (95% CI: 0.07 to 0.47%).

The most evidence-based approach combines morning bright-light therapy (10,000 lux for 30 minutes within 15 minutes of desired wake time) with low-dose melatonin 0.5 mg administered 5 to 6 hours before DLMO to advance the circadian phase. The AASM 2015 guideline specifically recommends strategically timed exogenous melatonin for DSWPD, citing the DLMO as the anchor for dosing time.

Blunted Peak Without Phase Shift

A flat profile (peak <20 pg/mL) with a DLMO in the normal timing window suggests pineal suppression rather than a phase disorder. Common reversible causes include:

• Beta-adrenergic blockers (atenolol, propranolol): suppress nocturnal melatonin by 30% to 50% by blocking pineal sympathetic input
• NSAIDs (ibuprofen, naproxen): chronic use may reduce melatonin by up to 50% through COX-mediated prostaglandin suppression
• Light exposure during sleep (including blue-light devices): even 100 lux of white light at 02:00 can suppress melatonin by 50% in sensitive individuals
• Alcohol: acute alcohol consumption at 19:00 to 20:00 reduces overnight melatonin area-under-the-curve by approximately 19%

A 1992 study by Stoschitzky et al. In the Journal of Cardiovascular Pharmacology confirmed that atenolol reduces nocturnal melatonin output by about 50% in hypertensive patients. Clinicians should review the full medication list before attributing a blunted profile to a primary endocrine disorder.

How to Raise Low Salivary Melatonin

Raising endogenous melatonin output starts with environmental and behavioral changes before pharmacologic intervention.

Light Management

Morning bright-light exposure advances the clock, but evening blue-light reduction is equally important for raising nocturnal melatonin. Switching to dim, warm lighting (<50 lux, color temperature <3,000 K) after 20:00 preserves the normal melatonin rise. Blue-light blocking glasses filtering wavelengths below 480 nm may reduce light-induced melatonin suppression by 50% or more. A 2017 randomized trial by Shechter et al. (N=14, JAMA Internal Medicine) showed that amber-tinted blue-light-blocking glasses worn for 2 hours before bed significantly improved sleep quality vs. Clear lenses.

Exogenous Melatonin for Phase Correction

When behavioral changes are insufficient, exogenous melatonin at physiological doses (0.5 mg) administered 5 hours before the current DLMO advances circadian phase by approximately 1 to 2 hours over 2 to 4 weeks. Higher doses (3 to 10 mg) increase total circulating melatonin but produce a longer half-life with morning grogginess and do not advance phase more effectively than 0.5 mg. The Endocrine Society guideline explicitly states: "We recommend low doses (0.5 mg) of melatonin for circadian phase-shifting effects rather than higher doses primarily used for their hypnotic effects." Full text available here.

Addressing Suppressant Medications

If beta-blockers are necessary, switching from atenolol or propranolol to a cardioselective beta-1 blocker with less central effect (such as bisoprolol) may partially restore nocturnal melatonin. Any medication adjustment requires direct coordination with the prescribing physician.

How to Lower High Salivary Melatonin (or Advance an Early DLMO)

An advanced DLMO (early melatonin rise) is corrected by phase-delaying interventions, not by blocking melatonin secretion directly.

Evening Bright-Light Therapy

Evening bright-light exposure (2,500 to 10,000 lux) delivered from approximately 20:00 to 22:00 suppresses early melatonin secretion and shifts DLMO later. A standardized protocol used in ASWPD clinical practice exposes patients to a 10,000-lux light box for 30 minutes beginning 2 hours before their current DLMO. Phase delays of 1 to 3 hours over 2 to 3 weeks are typical.

Chronotherapy

Progressive delay of bedtime by 1.5 to 3 hours per day until the desired sleep schedule is reached is a second option, though compliance is difficult. It is generally reserved for severe ASWPD when light therapy produces insufficient phase delay.

Collecting the Test Correctly: Factors That Invalidate Results

Sample quality is the single largest source of error on this test. Errors produce false-low readings (light exposure, food contamination) or false-high readings (exogenous melatonin, sample degradation from improper freezing).

The following collection rules apply to all DLMO-based salivary melatonin protocols:

• Maintain ambient light <10 lux (standard household candle-level lighting) throughout the entire collection window. Any brighter light exposure, even 15 seconds near a phone screen, can suppress melatonin within minutes.
• Do not eat, drink (water is acceptable), or brush teeth for 30 minutes before each sample.
• Avoid melatonin supplements, tryptophan supplements, and any sleep aids for at least 7 days before collection. Some commercial preparations have 10-day washout guidance.
• Keep samples in the provided tube, freeze them within 2 hours of collection if mailing the next day, and ship on ice. Salivary melatonin degrades measurably above 4°C over 48 hours.
• Collect samples at the same clock times on the test day as listed in the lab's protocol, regardless of how tired you feel. Deviating the collection schedule by even 30 minutes invalidates the DLMO calculation.

Clinicians reading the result should always cross-reference reported collection conditions with the curve shape. A completely flat curve in a young adult with no medications and good light compliance is diagnostically informative. A flat curve with a noted protocol deviation may simply reflect a failed collection.

Who Should Order This Test

The salivary melatonin profile is appropriate for patients with:

• Persistent difficulty falling asleep before 02:00 despite adequate sleep opportunity (probable DSWPD)
• Inability to stay awake past 20:00 with spontaneous waking before 04:00 (probable ASWPD)
• Shift work disorder with suspected circadian desynchrony confirmed by actigraphy
• Autism spectrum disorder or Smith-Magenis syndrome (known disrupted melatonin rhythms)
• Pre-treatment baseline before initiating exogenous melatonin, particularly in children
• Post-treatment monitoring to confirm phase shift after 6 to 8 weeks of light therapy or low-dose melatonin

The test is less useful for insomnia driven by anxiety, sleep apnea, restless legs syndrome, or poor sleep hygiene without an identifiable phase component. A thorough sleep history and actigraphy over 7 to 14 days should guide the decision.

Interpreting Results in Context: Age, Sex, and Season

Melatonin secretion varies substantially across the lifespan. Infants produce very little melatonin until approximately 3 months of age. Production peaks in children aged 1 to 5 (salivary peaks of 200 to 400 pg/mL), then declines through puberty and continues declining slowly into old age. Reference ranges must therefore be age-adjusted. Using the adult 80 to 120 pg/mL reference for a 6-year-old produces false-positive "high" readings, while applying pediatric ranges to a 70-year-old obscures genuine deficiency.

Sex differences are modest in adults. Some studies show women have slightly higher nocturnal melatonin than age-matched men, but the difference (<15%) is below the clinical decision threshold. Seasonal variation is more pronounced: DLMO occurs approximately 30 minutes earlier in winter than in summer at latitudes above 40°N, consistent with the longer photoperiod sensitivity of the pineal gland. A 2011 study by Lewy et al. (N=20) in the Proceedings of the National Academy of Sciences confirmed seasonal DLMO shifts and their relevance to Seasonal Affective Disorder pathophysiology.

For clinical phase-disorder diagnosis, the treating clinician should compare DLMO timing to the patient's own habitual sleep midpoint rather than to a population clock-time average. A DLMO at 23:00 is normal for someone sleeping 01:00 to 09:00, but it represents a severe phase delay in someone expected to start work at 06:00.